As three Covid-19 vaccines look ready to be rolled out soon, now one question is crossing the public mind where actually Bangladesh is in the line to have one.
Many health experts think that things are getting complicated for Bangladesh to get one anytime soon as the vaccine developed by AstraZeneca and Oxford University has triggered controversies.
They said Bangladesh has been mainly expecting to have the AstraZeneca-Oxford vaccine through the Serum Institute of India (SII) since the two other vaccines of Pfizer-BioNTech and Moderna are unsuitable for the country due to preservation-related problems.
Unlike the two, the AstraZeneca vaccine does not have to be stored at ultra-cold temperatures, making it easier to distribute in developing countries.
Scientists have, however, raised a question about the efficacy and results of the experimental Covid-19 vaccine, and AstraZeneca and Oxford University have also acknowledged a manufacturing error.
On November 5, Bangladesh signed an agreement to get 30 million doses of the AstraZeneca’s vaccine from India’s Serum Institute once it gets available, but the UK becomes the first country to approve Pfizer’s Covid-19 vaccine and its first shots to be rolled out next week.
Under the circumstances, local health experts said Bangladesh should now focus on other preventive measures like ensuring cent percent use of masks and encouraging people to follow health hygiene rules to contain the deadly virus alongside continuing strong efforts to have any other effective vaccine.
More homework needed on vaccine
Contacted, Dr Be-Nazir Ahmed, former director (disease control) of the DGHS, said Bangladesh has signed the deal with Serum to buy AstraZeneca’s vaccine, but there are now many questions about the trial results of the vaccine candidate.
“There’re also controversies over the effectiveness and trial process of the vaccines developed by China and Russia. So, we’ve to carefully observe the developments relating to the vaccines around the world,” he said.
The vaccine expert said though the two American experimental vaccines look highly effective, those are unsuitable for Bangladesh due to temperature-related problems. “So, it’s true that Bangladesh’s vaccine fate will hang in balance if the AstraZeneca’s vaccine finally fails to get approval.”
In this situation, Dr Be-Nazir said, Bangladesh needs some solid homework on the vaccine. “We need to have a vaccine committee and some scientific ones to evaluate the developments over the vaccine and assess which one is suitable for Bangladesh. We need to check our existing cold chain and make it ready to preserve if any suitable vaccine is found.”
Vaccine approval a long process
Former World Health Organisation (WHO) Regional Adviser Muzaherul Huq said the vaccine which has efficacy, quality and safety is still not found. “Some potential vaccine candidates are still at the trial stage.”
Once the trials are completed, Muzaher said, a committee of WHO will examine whether that have been conducted systematically following the proper guidelines and scrutinise all the findings of the trials.